Drug Profile
BPX 201
Alternative Names: AP-1903 activated BPX 201; BPX-201; Rimiducid activated BPX 201; Second generation autologous DeCIDe vaccine (BPX-201) - Bellicum PharmaceuticalsLatest Information Update: 05 Apr 2024
Price :
$50
*
At a glance
- Originator Bellicum Pharmaceuticals
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 23 Feb 2024 Discontinued - Phase-I for Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in USA (Intradermal) as Bellicum Pharmaceuticals has winded down its business and no longer active
- 28 Dec 2019 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Hormone refractory, Metastatic disease) in USA (Intradermal, Injection)
- 01 Sep 2017 Phase-I development in Prostate-cancer(Combination therapy, Hormone refractory, Metastatic disease) is ongoing in USA (Intradermal, Injection)